Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch.
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects.
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth.
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche.
